Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Overview and Strategic Initiatives
ABBV logo

Skyrizi and Rinvoq Drive 9% Revenue Growth as AbbVie Navigates 49% Humira Decline

ABBV10-KFiling Date: 2/20/2026
AbbVie Inc.
Description

What this story covers

AbbVie’s 2025 10-K reveals a successful transition as Skyrizi and Rinvoq now comprise 42% of revenue, offsetting a 49% drop in Humira sales. Despite regulatory pricing pressures and legal challenges, the company remains a $61.2 billion powerhouse.

Story snapshot

CompanyAbbVie Inc.
TickerABBV
VariantStandard detailed
Duration13:40
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0001551152-26-000008
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in